Eltanexor is under clinical development by Karyopharm Therapeutics and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). According to GlobalData, Phase II drugs for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Eltanexor’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Eltanexor is under development for the treatment of metastatic hormone refractory (castration-resistant, androgen-independent) prostate cancer, acute myeloid leukemia (AML), squamous cell carcinoma of the penis, nasopharyngeal cancer, myelodysplastic syndrome, adenocarcinoma of prostate and colon or rectum, relapsed or refractory multiple myeloma, metastatic colorectal cancer, refractory multiple myeloma, acute lymphoblastic leukemia, myelofibrosis, gastric cancer, gastroesophageal (GE) junction carcinomas, diffuse large B-cell lymphoma, triple-negative breast cancer (TNBC) and solid tumors. The drug candidate is administered orally. KPT-8602 acts by targeting exportin 1 and is a second generation SINE compound. The development is based on the selective inhibitor of nuclear export (SINE) technology platform. It was also under development for the treatment of acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL).
Karyopharm Therapeutics overview
Karyopharm Therapeutics (Karyopharm Therapeutic) discovers and develops novel drugs for the treatment of cancer and other diseases. The company’s core technology harnesses the inhibition of nuclear export as a mechanism to treat patients suffering from cancer. Karyopharm’s lead product, Xpovio, is recommended for the treatment of multiple myeloma, and relapsed or refractory diffuse large B-cell lymphoma. Its pipeline drug candidates include selinexor, eltanexor, verdinexor, and KPT-9274. Karyopharm’s drug candidates are indicated for the treatment of various hematological and solid tumor malignancies including multiple myeloma, diffuse large B-cell lymphoma, liposarcoma, glioblastoma and endometrial cancer. The company has operations in the US, Israel and Germany. Karyopharm is headquartered in Newton, Massachusetts, the US.
For a complete picture of Eltanexor’s drug-specific PTSR and LoA scores, buy the report here.